arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Neuraxis, INC

NRXS
$7.09 ▲ +0.19 (+2.75%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
5 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Neuraxis, INC faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $64.4M
Dividend Yield
Revenue Growth 32.9%
Op. Margin -219.4%
ROIC -182.0%
FCF / Share $-0.71
Trailing P/E
Price / Book 22.2x
FCF Yield
Debt / Equity 0.04
info Valuation on last close. End-of-day price, Aug 7, 2026.

5-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.57M
↑ +32.9%
Net Income Profit after all expenses
$-7.80M
↑ +5.4%
Operating Margin Operating profit as % of sales
-219.4%
↑ +17.7% 0th
FCF / Share Free cash flow per share
$-0.71
↑ +19.6%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
1
Financial Health
51
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 18 quarters